

BALGOPAL COMMERCIAL LIMITED

CIN: L51109MH1982PLC368610

Date: 13-02-2023

To,
The Department of Corporate Services,
BSE Limited,
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001

Scrip Code: 539834

Sir/Madam,


Subject: Newspaper Publication under Regulation 47 of SEBI (LODR), Regulations, 2015

The Board at their meeting held on 11th, February, 2023 approved the unaudited Financial Results of the Company for the quarter ended on 31st December, 2022. In continuation to the same, the newspaper clipping duly published in English Newspaper (All edition) and Marathi Newspaper (Mumbai edition) dated 12.02.2023 is enclosed herewith.

We hereby request you to take the same on your record.

For Balgopal Commercial Ltd

BALGOPAL COMMERCIAL LTD



Director/Authorised Signatar

Vijay Laltaprasad Yadav
Managing Director
DIN: 02904370

ADDRESS: Flat No. B-002, Dreamax Vega, Upadhyay Compound, Pump House,
Jijamata Road, Andheri (East), Mumbai-400093
Website: www.bcommercial.org/ Email ID: info@bcommercial.org
Contact: 9324922533

| BALGOPAL COMMERCIAL LIMITED CIN: L51109MH1982PLC368610 Flat No. B-002, Dreamax Vega, Upadhay Compound, Pump House, Jijamata Road, Andheri (East) Mumbai-400093 UNAUDITED FINANCIAL RESULTS FOR QUARTER AND NINE MONTHS ENDED ON 31ST DECEMBER, 2022 (Amount: in Rs.000 except eps) | | | | |
|--|---|-----------------------------|---------------------------------|-----------------------------|
| Sl. No. | PARTICULARS | Quarter ending (31/12/2022) | Nine Months ending (31/12/2022) | Quarter ending (31/12/2021) |
| | | Unaudited | Unaudited | Unaudited |
| | | 1 | Total income from operations | 38,855.23 |
| 2 | Net Profit/ (Loss) for the period (before tax, Exceptional and/or Extraordinary items) | 18,782.28 | 39,325.13 | (20,784.20) |
| 3 | Net Profit/ (Loss) for the period before tax (after Exceptional and/or Extraordinary items) | 18,782.28 | 39,325.13 | (20,784.20) |
| 4 | Net Profit/ (Loss) for the period after tax (after Exceptional and/or Extraordinary items) | 17,687.48 | 39,482.16 | (18,981.80) |
| 5 | Total Comprehensive Income for the period [(Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)] | 17,687.48 | 39,482.16 | (18,981.80) |
| 6 | Equity Share Capital | 1,65,100.00 | 1,65,100.00 | 1,65,100.00 |
| 7 | Earning Per Share (of Rs. 10/-each) (for continuing and discontinuing operations) (not annualized) | 1.07 | 2.39 | (1.15) |
| | Basic | 1.07 | 2.39 | (1.15) |
| | Diluted | 1.07 | 2.39 | (1.15) |

NOTE:
The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the BSE Website (www.bseindia.com) and on the website of the Company www.bcommercial.org. The Statutory Auditors of the Company have carried a Limited Review Report of the above results.

For BALGOPAL COMMERCIAL LIMITED
Sd/-
Vijay Laltraprasad Yadav
Managing Director
DIN: 02904370

Place: Mumbai
Date: 11th February, 2023

| GUJARAT SIDHEE CEMENT LIMITED (CIN : L26940GJ1973PLC002245) At: Sidheegram, PO - Prashnavada BO, Via Sutrapada SO - 362 275, Off Veraval Kodinar Highway, Dist: Gir Somnath, (Gujarat). Phone: 02876-268200, Fax: 02876-286540 E-Mail: cfo@mehtagroup.com Website: www.mehtagroup.com | | | | | | | |
|---|---------------|----------------|---------------|-------------------|---------------|---------------|--|
| EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2022 | | | | | | | |
| Particulars | Quarter Ended | | | Nine Months ended | | Year Ended | |
| | Dec. 31, 2022 | Sept. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2022 | Dec. 31, 2021 | Mar. 31, 2022 | |
| | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) | |
| | ₹ in Lakhs | ₹ in Lakhs | ₹ in Lakhs | ₹ in Lakhs | ₹ in Lakhs | ₹ in Lakhs | |
| Total income from Operations | 22,414.28 | 14,330.52 | 17,919.84 | 55,695.19 | 50,548.98 | 71,046.55 | |
| Net Profit / (Loss) for the period before tax | 509.24 | (2,313.59) | 815.63 | (1,020.68) | 2,557.22 | 3,086.57 | |
| Net Profit / (Loss) for the period after tax | 329.07 | (1,542.74) | 517.70 | (664.29) | 1,695.12 | 2,016.62 | |
| Total Comprehensive income after tax | (279.37) | (76.78) | (2,428.79) | (1,113.37) | 2,770.16 | 1,916.57 | |
| Equity Share Capital | 8,943.62 | 8,941.53 | 8,918.03 | 8,943.62 | 8,918.03 | 8,927.12 | |
| Other Equity | | | | | | 38,594.17 | |
| Basic Earnings per Share of ₹10 each (not annualized) - In ₹ | 0.37 | (1.73) | 0.58 | (0.74) | 1.91 | 2.27 | |
| Diluted Earnings per Share of ₹10 each (not annualized) - In ₹ | 0.37 | (1.73) | 0.58 | (0.74) | 1.90 | 2.26 | |

Note : The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchanges website www.bseindia.com and www.nseindia.com and Company's website www.gujaratsidheecementlimited.com

By the Order of the Board,
For Gujarat Sidhee Cement Limited
(M.S. Gilotra)
Managing Director
DIN : 00152190

Place : Mumbai
Date : February 10, 2023

| KDDL LIMITED (CIN : L33302HP1981PLC008123) Regd. Office: Plot No. 3, Sector - III, Parwanoo, Distt. Solan (H.P.) - 173220 Tel.: +91 172 2548223 / 24 Fax : +91 172 2548302 Website: www.kddl.com ; Email id: investor.complaints@kddl.com | | | | | | | |
|---|--|--------------------------------|--|---|--------------------------------|--|---|
| STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2022 (Rs. in Lakhs except earnings per share) | | | | | | | |
| S. No. | Particulars (Refer notes below) | Standalone | | | Consolidated | | |
| | | Quarter ended 31 December 2022 | Corresponding Quarter ended 31 December 2021 | Year to date figures for the current period ending 31 December 2022 | Quarter ended 31 December 2022 | Corresponding Quarter ended 31 December 2021 | Year to date figures for the current period ending 31 December 2022 |
| | | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) |
| 1 | Total income from operations | 7929 | 5806 | 27602 | 31704 | 26147 | 83231 |
| 2 | Net Profit/(Loss) for the period from ordinary activities (before tax, exceptional items and/or extraordinary items) | 1559 | 788 | 7227 | 4185 | 2316 | 7778 |
| 3 | Net Profit/(Loss) for the period from ordinary activities before tax (after exceptional items and/or extraordinary items) | 1559 | 788 | 7227 | 4185 | 2316 | 7778 |
| 4 | Net Profit/(Loss) for the period from ordinary activities after tax (after exceptional items and/or extraordinary items) | 1163 | 557 | 5656 | 3087 | 1651 | 5572 |
| 5 | Total Comprehensive Income / (Loss) for the period [comprising profit for the period (after tax) and other comprehensive income (after tax)] | 1163 | 557 | 5619 | 3115 | 1691 | 5547 |
| 6 | Paid-up equity share capital (Face value in Rs 10 per share) | 1274 | 1274 | 1274 | 1274 | 1274 | 1274 |
| 7 | Earnings per share (of Rs 10/- each) (not annualized): | | | | | | |
| | (a) Basic (Rs) | 9.13 | 4.37 | 44.41 | 17.92 | 10.75 | 29.39 |
| | (b) Diluted (Rs) | 9.13 | 4.37 | 44.41 | 17.92 | 10.75 | 29.39 |

Notes:
1. The above Unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 11 February 2023. The Unaudited financial results for the current quarter & nine months ended 31 December 2022 have been subjected to limited review by the Statutory Auditors of the Company. The unmodified review report of the Statutory Auditors is being filed with the BSE and National Stock Exchange.
2. The above is the extract of the detailed format of the Unaudited quarterly financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited quarterly financial results are available on the websites of the Stock Exchanges i.e. www.bseindia.com and www.nse.india.com and the company's website www.kddl.com

For and on the behalf of Board of Directors
Sanjeev Kumar Masown
(Whole Time Director)
DIN-03542390

Place: Chandigarh
Date: 11 February 2023



GLENMARK PHARMACEUTICALS LIMITED

Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mahalaxmi, Mumbai - 400 026.
Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri (East), Mumbai - 400 099.
Tel No.: +91-22-4018 9999 Fax No.: +91-22-4018 9986
Email: complianceofficer@glenmarkpharma.com Website: www.glenmarkpharma.com
CIN: L24299MH1977PLC019982

Statement of unaudited financial results for the quarter and nine months ended 31 December, 2021

(All amounts in million of Indian Rupees, unless otherwise stated)

| Particulars | Standalone | | | | | | Consolidated | | | | | |
|---|--------------------------|--------------------------|--------------------------|------------------------------|------------------------------|-----------------------|--------------------------|--------------------------|--------------------------|------------------------------|------------------------------|-----------------------|
| | Quarter ended 31/12/2021 | Quarter ended 30/09/2021 | Quarter ended 31/12/2020 | Nine months ended 31/12/2021 | Nine months ended 31/12/2020 | Year ended 31/03/2021 | Quarter ended 31/12/2021 | Quarter ended 30/09/2021 | Quarter ended 31/12/2020 | Nine months ended 31/12/2021 | Nine months ended 31/12/2020 | Year ended 31/03/2021 |
| | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| I Revenue from operations | | | | | | | | | | | | |
| (a) Net sales | 20,073.59 | 21,598.94 | 19,498.23 | 62,964.93 | 56,277.60 | 74,509.11 | 31,414.72 | 31,254.26 | 27,587.36 | 92,130.46 | 79,761.37 | 108,060.26 |
| (b) Other operating income | 256.95 | 209.72 | 226.55 | 595.44 | 898.05 | 1,170.22 | 319.42 | 220.21 | 280.27 | 727.10 | 1,078.92 | 1,379.03 |
| Total revenue from operations | 20,330.54 | 21,808.66 | 19,724.78 | 63,560.37 | 57,175.65 | 75,679.33 | 31,734.14 | 31,474.47 | 27,867.63 | 92,857.56 | 80,840.29 | 109,439.29 |
| II Other income | 2,167.43 | 806.96 | 811.27 | 4,356.47 | 138.95 | 150.90 | 138.95 | (130.72) | 150.90 | 594.72 | 417.23 | 502.16 |
| III Total income (I + II) | 22,497.97 | 22,615.62 | 20,536.05 | 67,916.84 | 59,969.45 | 79,641.70 | 31,873.09 | 31,343.75 | 28,018.53 | 93,452.28 | 81,257.52 | 109,941.45 |
| IV Expenses | | | | | | | | | | | | |
| (a) Cost of materials consumed | 6,426.96 | 8,144.13 | 6,903.32 | 23,030.61 | 20,324.09 | 26,782.60 | 7,202.05 | 8,513.99 | 7,828.98 | 24,888.23 | 23,519.30 | 31,378.05 |
| (b) Purchases of stock-in-trade | 1,255.58 | 1,180.91 | 897.98 | 3,838.10 | 2,319.22 | 3,159.55 | 2,744.00 | 2,862.73 | 2,532.35 | 8,792.64 | 5,726.96 | 7,502.69 |
| (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | 49.98 | (44.53) | (197.44) | 46.72 | (313.05) | 52.40 | 772.89 | 58.81 | (1,247.66) | (136.70) | (1,641.78) | (1,892.54) |
| (d) Employee benefits expense | 2,943.66 | 3,491.84 | 2,806.54 | 9,076.72 | 8,554.66 | 11,073.96 | 5,859.91 | 6,873.29 | 5,966.43 | 18,697.39 | 18,065.03 | 23,437.07 |
| (e) Finance costs | 497.72 | 532.45 | 830.41 | 1,620.31 | 2,033.91 | 2,658.98 | 666.95 | 689.46 | 954.07 | 2,112.44 | 2,697.79 | 3,531.13 |
| (f) Depreciation, amortisation and impairment expense | 407.98 | 396.83 | 412.12 | 1,179.22 | 1,138.15 | 1,508.15 | 1,189.30 | 1,231.90 | 1,151.98 | 3,551.92 | 3,324.85 | 4,435.54 |
| (g) Other expenses | 4,549.54 | 4,441.25 | 4,012.02 | 12,301.86 | 10,947.38 | 15,707.41 | 8,223.77 | 7,263.96 | 7,486.81 | 22,047.01 | 19,561.25 | 28,170.21 |
| Total expenses (IV) | 16,131.42 | 18,142.88 | 15,664.95 | 51,093.54 | 45,004.36 | 60,943.05 | 26,658.87 | 27,494.14 | 24,672.96 | 79,952.93 | 71,253.40 | 96,562.15 |
| V Profit/(loss) before exceptional items and tax (III - IV) | 6,366.55 | 4,472.74 | 4,871.10 | 16,823.30 | 14,965.09 | 18,698.65 | 5,214.22 | 3,849.61 | 3,345.57 | 13,499.35 | 10,004.12 | 13,379.30 |
| VI Exceptional items loss/(gain) (Refer note 5) | - | (4,303.33) | (459.02) | (4,303.33) | (738.92) | (738.92) | 1,783.80 | - | (134.15) | 1,783.80 | (445.45) | (445.45) |
| VII Profit/(loss) before tax (V - VI) | 6,366.55 | 8,776.07 | 5,330.12 | 21,126.63 | 15,704.01 | 19,437.57 | 3,430.42 | 3,849.61 | 3,479.72 | 11,715.55 | 10,449.57 | 13,824.75 |
| VIII Tax expense : | | | | | | | | | | | | |
| Current tax | 1,406.48 | 1,250.76 | 932.03 | 3,708.13 | 2,746.89 | 3,436.18 | 1,631.30 | 1,232.01 | 1,212.43 | 4,309.30 | 3,902.49 | 4,981.40 |
| Deferred tax | (525.12) | (17.27) | (25.16) | (503.44) | (119.64) | (493.08) | (598.39) | (130.45) | (214.58) | (804.58) | (815.06) | (857.53) |
| IX Profit/(loss) for the period (VII - VIII) | 5,485.19 | 7,542.58 | 4,423.25 | 17,921.94 | 13,076.76 | 16,494.47 | 2,397.51 | 2,748.05 | 2,481.79 | 8,210.83 | 7,362.14 | 9,700.88 |
| Profit/(loss) for the period attributable to: | | | | | | | | | | | | |
| - Non-controlling interests | - | - | - | - | - | - | 178.49 | 171.45 | 0.83 | 349.57 | 1.73 | 0.50 |
| - Owners of the Company | 5,485.19 | 7,542.58 | 4,423.25 | 17,921.94 | 13,076.76 | 16,494.47 | 2,219.02 | 2,576.60 | 2,480.96 | 7,861.26 | 7,360.41 | 9,700.38 |
| X Other comprehensive income | | | | | | | | | | | | |
| A (i) Items that will not be reclassified to profit or loss | 11.59 | (21.48) | 5.11 | 15.76 | 16.06 | 32.33 | 17.28 | (67.36) | (0.51) | (24.49) | (138.03) | 51.79 |
| (ii) Income tax relating to items that will not be reclassified to profit or loss | (4.77) | 8.23 | (1.79) | (5.50) | (5.62) | (7.49) | (4.99) | 15.16 | (0.58) | 1.65 | 14.76 | (7.47) |
| B (i) Items that will be reclassified to profit or loss | - | - | - | - | - | - | 82.22 | (532.39) | 1,125.91 | 525.78 | 1,094.38 | 719.81 |
| (ii) Income tax relating to items that will be reclassified to profit or loss | - | - | - | - | - | - | (10.88) | 5.44 | (77.86) | (72.76) | 121.04 | 102.68 |
| XI Total comprehensive income | 5,492.01 | 7,529.33 | 4,426.57 | 17,932.20 | 13,087.20 | 16,519.31 | 2,481.14 | 2,168.90 | 3,528.75 | 8,641.01 | 8,454.29 | 10,567.69 |
| XII Total comprehensive income attributable to: | | | | | | | | | | | | |
| - Non-controlling interests | - | - | - | - | - | - | 178.52 | 171.58 | 0.83 | 349.73 | 1.73 | 0.50 |
| - Owners of the Company | 5,492.01 | 7,529.33 | 4,426.57 | 17,932.20 | 13,087.20 | 16,519.31 | 2,302.62 | 1,997.32 | 3,527.92 | 8,291.28 | 8,452.56 | 10,567.19 |
| XIII Paid up Equity Share Capital, Equity Shares of Rs. 1/- each | 282.17 | 282.17 | 282.17 | 282.17 | 282.17 | 282.17 | 282.17 | 282.17 | 282.17 | 282.17 | 282.17 | 282.17 |
| XIV Other equity | | | | | | 147,812.89 | | | | | | 70,364.10 |
| XV Earning per share (EPS) (of Re 1/- each) (not annualized)* | | | | | | | | | | | | |
| Basic EPS (in Rupees) | 19.44 | 26.73 | 15.68 | 63.52 | 46.34 | 58.46 | 7.86 | 9.13 | 8.80 | 27.86 | 26.09 | 34.38 |
| Diluted EPS (in Rupees) | 19.44 | 26.73 | 15.68 | 63.52 | 46.34 | 58.46 | 7.86 | 9.13 | 8.80 | 27.86 | 26.09 | 34.38 |

* except for the year ended 31 March

- Notes:**
- The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
 - The above results were reviewed by the Audit Committee at its meeting held on 10 February 2022 and approved by the Board of Directors at their meetings held on 11 February, 2022.
 - The results for the quarter and Nine months ended 31 December, 2021 presented were subjected to a "Limited Review" by statutory auditors of the Company who have issued an unmodified report on the said results.
 - The date of implementation of the Code on Wages 2019 and the Code on Social Security, 2020 is yet to be notified by the Government. The Company will assess the impact of these Codes and give effect in the financial results when the Rules/Schemes thereunder are notified.
 - Exceptional item:
Exceptional item of Rs. 1,783.80 in consolidated result for the quarter and nine months ended 31 December 2021 comprises of impairment of certain intangible assets. On 3 August 2021, Glenmark Life Sciences Limited (GLS) completed allotment of shares as part of its Initial Public Offering (IPO) and Offer for Sale (OFS). The company offered 6.3 million equity shares of Rs 2 each through OFS and resulted in a gain of Rs 4,303.33 (net of related expenses and cost of equity shares) and recorded as an exceptional item in the standalone financial results. Pursuant to requirements of Ind AS 110 para 23 and 896 such gain and tax thereon is directly recognised in equity in consolidated financial statements. Post the sale and IPO, the Company's holding in equity shares of GLS has reduced from 100% to 82.84 %.
Exceptional items in the standalone financial results for the quarter and nine months ended 31 December, 2020 of Rs. 459.02 and Rs. 738.92 respectively and in the consolidated financial results for the quarter and nine months ended 31 December, 2020 of Rs. 134.15 and Rs. 445.45 respectively are on account of gain from transfer of intimate hygiene brand Vwash, Momat brands in certain geographies, sale of IP assets and reimbursement of onetime costs.
 - The Chief Operating Decision Maker ("CODM") reviews the financial performance at pharmaceutical business level, comprising of generics and active pharmaceutical ingredient components, which are interlinked and inter-dependent, therefore, the Company has only one reportable segment, i.e., Pharmaceuticals.
 - As at 31 December, 2021, pursuant to Employee Stock Options Scheme 2016, 404,247 options were outstanding, which upon exercise are convertible into equivalent number of equity shares.
 - The list of subsidiaries as of 31 December 2021 is provided in Annexure A.
 - The Group continues to closely monitor the impact of the COVID-19 pandemic on all aspects of its business, including how it has impacted and how it will impact its customers, employees, vendors and business partners. The management has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, assessment for impairment of goodwill, investments, intangible assets, inventory, based on the information available to date, both internal and external, while preparing the financial results for the quarter and Nine months ended 31 December, 2021.
 - Diluted EPS has been computed considering the effect of conversion of ESOPs.
 - Previous period's figures have been re-grouped/re-classified to render them comparable with the figures of the current period.

- Annexure A**
List of entities included in the consolidated financial results for quarter and nine months ended 31 December 2021
- <

